Arkadios Wealth Advisors Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Arkadios Wealth Advisors increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 7.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,705 shares of the company’s stock after purchasing an additional 3,251 shares during the period. Arkadios Wealth Advisors owned 0.10% of Omnicell worth $1,633,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sei Investments Co. purchased a new position in shares of Omnicell in the fourth quarter worth $313,000. KLP Kapitalforvaltning AS bought a new stake in Omnicell during the fourth quarter valued at approximately $436,000. Vanguard Group Inc. boosted its stake in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after acquiring an additional 28,573 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Omnicell in the 4th quarter worth $5,372,000. Finally, Alliancebernstein L.P. increased its position in Omnicell by 4.3% in the fourth quarter. Alliancebernstein L.P. now owns 55,922 shares of the company’s stock worth $2,490,000 after buying an additional 2,316 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OMCL. Bank of America upped their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Benchmark lowered their target price on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 12th. Piper Sandler reiterated an “overweight” rating on shares of Omnicell in a research report on Friday, May 23rd. Finally, Wells Fargo & Company boosted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.33.

Omnicell Trading Down 4.0%

NASDAQ OMCL opened at $29.76 on Friday. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 59.52, a price-to-earnings-growth ratio of 9.05 and a beta of 0.77. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.42. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74. The company’s 50-day simple moving average is $29.27 and its two-hundred day simple moving average is $33.18.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company had revenue of $290.56 million during the quarter, compared to analysts’ expectations of $275.57 million. During the same period last year, the business earned $0.51 EPS. Omnicell’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.